Aurora Cannabis Inc. (NYSE: ACB) shares are -64.12% down in the year-to-date (YTD) period and have moved -5.10% or -$0.5 lower in the latest trading session. However, stock’s trailing 12-month performance remains nearly +75.47% lower. Comparatively, the stock is -66.59% down YTD and -34.97% over the trailing 3-month period. If we look at the shorter duration, its week performance is -2.00% and -10.75% over the month.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
On May 22, 2020, Jefferies recommended the ACB stock is a Underperform, while earlier, Stifel had Upgrade the stock as a Hold on June 24, 2020. 3 of the 19 analysts rate the stock as a “Sell”, while 0 has rated it as “Underweight”. 3 recommend buying, with 1 rating it as an Overweight.
The stock currently trades at $9.30. The forecasts give the Aurora Cannabis Inc. stock a price target range of $21.40 on the higher side while at least one analyst think the stock could plunge to a low of $7.70. The two limits represent an upside potential of 56.54% or -20.78%.
Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN), on the other hand, is trading around $0.91 with a market cap of $56.71M and analyst research firms have a negative stance on its shares. Some analysts are even forecasting -$0.28 per share in earnings this year on a short term (1 year) basis.
Let us briefly look at the Diffusion Pharmaceuticals Inc. (DFFN) financials, with a focus on its operating details as indicated in its earnings report for the last quarter.
Company balance sheet and cash flow
DFFN’s operating expenses over the recent quarter were at $26000.0. This represented a 99.29% of the company’s total revenues which amounted $3.66 million. With this in place, we can see that the company’s diluted EPS declined -$0.10 on the year-over-year period, shrinking to -$0.63 as given in the last earnings report.
In terms of the balance sheet & cash flow as of (Sep 2020), the total assets figure advanced to $35.99 million from $21.06 million over the previous quarter. The company’s free cash flow for the quarter was -$6.65 million.
Insiders have transacted a total of 0 times at Diffusion Pharmaceuticals Inc. over the last 6 months, with insider purchases undertaken 0 times and accounting for 0 shares. Insider sales totaled 0 shares over the same period, with these deals completed in 0 transactions. Looking at these numbers, we realize that net purchases over that period are 0.0 shares. Insiders now hold a total of 149.12k shares after the latest sales, with 0.00% net shares purchased.
Insiders own 0.23% of the company shares, while shares held by institutions stand at 11.00% with a share float percentage of 63.83M. Investors are also buoyed by the number of investors in a company, with Diffusion Pharmaceuticals Inc. having a total of 22 institutions that hold shares in the company.